Switch theme
Sign up to access all valuation multiples
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
2011
119
LTM Revenue $13.5M
LTM EBITDA -$111M
$413M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Inventiva has a last 12-month revenue (LTM) of $13.5M and a last 12-month EBITDA of -$111M.
In the most recent fiscal year, Inventiva achieved revenue of $10.3M and an EBITDA of -$187M.
Inventiva expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Inventiva valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.5M | XXX | $10.3M | XXX | XXX | XXX |
| Gross Profit | $13.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$111M | XXX | -$187M | XXX | XXX | XXX |
| EBITDA Margin | -819% | XXX | -1810% | XXX | XXX | XXX |
| EBIT | -$106M | XXX | -$106M | XXX | XXX | XXX |
| EBIT Margin | -782% | XXX | -1022% | XXX | XXX | XXX |
| Net Profit | -$164M | XXX | -$207M | XXX | XXX | XXX |
| Net Margin | -1211% | XXX | -2003% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Inventiva's stock price is EUR 3 (or $3).
Inventiva has current market cap of EUR 410M (or $460M), and EV of EUR 367M (or $413M).
See Inventiva trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $413M | $460M | XXX | XXX | XXX | XXX | $-2.41 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Inventiva has market cap of $460M and EV of $413M.
Inventiva's trades at 39.9x EV/Revenue multiple, and -2.2x EV/EBITDA.
Equity research analysts estimate Inventiva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inventiva has a P/E ratio of -2.8x.
See valuation multiples for Inventiva and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $460M | XXX | $460M | XXX | XXX | XXX |
| EV (current) | $413M | XXX | $413M | XXX | XXX | XXX |
| EV/Revenue | 30.5x | XXX | 39.9x | XXX | XXX | XXX |
| EV/EBITDA | -3.7x | XXX | -2.2x | XXX | XXX | XXX |
| EV/EBIT | -3.9x | XXX | -3.9x | XXX | XXX | XXX |
| EV/Gross Profit | 30.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.8x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | -5.4x | XXX | -4.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInventiva's last 12 month revenue growth is 76%
Inventiva's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Inventiva's rule of 40 is -508% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inventiva's rule of X is -629% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Inventiva and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 76% | XXX | 76% | XXX | XXX | XXX |
| EBITDA Margin | -819% | XXX | -1810% | XXX | XXX | XXX |
| EBITDA Growth | -15% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -508% | XXX | -1734% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -629% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 988% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1122% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inventiva acquired XXX companies to date.
Last acquisition by Inventiva was XXXXXXXX, XXXXX XXXXX XXXXXX . Inventiva acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Inventiva founded? | Inventiva was founded in 2011. |
| Where is Inventiva headquartered? | Inventiva is headquartered in France. |
| How many employees does Inventiva have? | As of today, Inventiva has 119 employees. |
| Who is the CEO of Inventiva? | Inventiva's CEO is Mr. Frederic Cren. |
| Is Inventiva publicy listed? | Yes, Inventiva is a public company listed on PAR. |
| What is the stock symbol of Inventiva? | Inventiva trades under IVA ticker. |
| When did Inventiva go public? | Inventiva went public in 2017. |
| Who are competitors of Inventiva? | Similar companies to Inventiva include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Inventiva? | Inventiva's current market cap is $460M |
| What is the current revenue of Inventiva? | Inventiva's last 12 months revenue is $13.5M. |
| What is the current revenue growth of Inventiva? | Inventiva revenue growth (NTM/LTM) is 76%. |
| What is the current EV/Revenue multiple of Inventiva? | Current revenue multiple of Inventiva is 30.5x. |
| Is Inventiva profitable? | Yes, Inventiva is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Inventiva? | Inventiva's last 12 months EBITDA is -$111M. |
| What is Inventiva's EBITDA margin? | Inventiva's last 12 months EBITDA margin is -819%. |
| What is the current EV/EBITDA multiple of Inventiva? | Current EBITDA multiple of Inventiva is -3.7x. |
| What is the current FCF of Inventiva? | Inventiva's last 12 months FCF is -$76.5M. |
| What is Inventiva's FCF margin? | Inventiva's last 12 months FCF margin is -565%. |
| What is the current EV/FCF multiple of Inventiva? | Current FCF multiple of Inventiva is -5.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
